In September 2025, the Company launched AboutNAD®, a next-generation digital platform designed to serve as the leading online resource for scientific advancements in NAD+ research and healthy aging.

Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year ...

Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be ...

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

Alamar Biosciences, Inc. (Alamar), a leader in precision proteomics dedicated to advancing the early detection of disease, is ...

Investors in Pacira BioSciences, Inc. PCRX need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 16, 2026 $12.50 Call had some of the highest ...

Cogent Biosciences, Inc. (NASDAQ:COGT) is among the 20 Best Performing Stocks in 2025. Based on a research note dated January ...

Holliston biotechnology firm Harvard Bioscience continued its fourth quarter momentum with revenue up 14% in the first quarter of 2021 when compared to the first quarter of 2020. Holliston ...

Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 ...